|Bid||0.0000 x 800|
|Ask||0.0000 x 1800|
|Day's Range||4.0100 - 4.1900|
|52 Week Range||3.1050 - 11.9300|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.64|
Kindred (KIN) expands an agreement with Vaxart for the manufacturing of the latter's oral vaccine for COVID-19 and other vaccine candidates.
Vaxart (NASDAQ: VXRT) is gearing up for a potential roll-out of its experimental COVID-19 vaccine. The clinical-stage biotechnology company is expanding its partnership with Kindred Biosciences (NASDAQ: KIN) to manufacture its oral vaccine candidate for the novel coronavirus. Under the terms of the deal, Kindred's plants will produce bioreactors for Vaxart's clinical trials.
Centaur Biopharmaceutical Services Inc. (Centaur), a wholly-owned subsidiary of Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), today announced an expanded agreement between KindredBio and Vaxart, Inc. (Nasdaq: VXRT) under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and other vaccine candidates.